The UK-based drug development startup AdoRx Therapeutics is funded by Epidarex Capital and Sixth Element Capital. AdoRx Therapeutics is working to develop novel cancer treatments that target the adenosine pathway. Adenosine is a key component of the tumour microenvironment that helps cancer avoid the immune system.
